Caris Life Sciences
Caris Life Sciences, a leading player in the precision medicine industry, is headquartered in France and operates extensively across Europe and North America. Founded in 2008, the company has made significant strides in advancing cancer care through its innovative molecular profiling services. Caris Life Sciences offers a unique suite of products, including comprehensive genomic profiling and biomarker testing, which empower healthcare providers to tailor treatments to individual patients. Their commitment to precision medicine has positioned them as a trusted partner in oncology, with notable achievements in improving patient outcomes. With a focus on integrating advanced technologies and data analytics, Caris Life Sciences continues to set benchmarks in the industry, driving forward the future of personalised medicine.
DitchCarbon Score
How does Caris Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Caris Life Sciences's score of 23 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Caris Life Sciences's reported carbon emissions
In 2023, Caris Life Sciences reported a Scope 3 intensity of approximately 0.00037 kg CO2e per € gross profit. This figure reflects the company's commitment to understanding and managing its carbon footprint, particularly in its upstream activities. In 2022, the Scope 3 intensity was slightly higher at about 0.00049 kg CO2e per € gross profit, indicating a positive trend towards reducing emissions relative to revenue. Currently, Caris Life Sciences has not disclosed specific targets for emissions reductions or any formal climate pledges. The absence of Scope 1 and Scope 2 emissions data suggests that the company may still be in the early stages of comprehensive emissions reporting. However, the focus on Scope 3 emissions highlights an awareness of the broader impact of its operations. As the industry increasingly prioritises sustainability, Caris Life Sciences's efforts to monitor and report on its carbon emissions are crucial for aligning with global climate commitments and enhancing its environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Caris Life Sciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
